# OnCo record paper-harmoni-2-lancet-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-harmoni-2-lancet-2025" ;
  schema:name "HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer"@en ;
  schema:description "In the first randomised trial to beat pembrolizumab directly, a single antibody that blocks both PD-1 and VEGF nearly doubled the time to progression in PD-L1-positive lung cancer, though survival data were still immature."@en ;
  schema:url <https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=HARMONi-2+ivonescimab+pembrolizumab+Lancet>, <https://clinicaltrials.gov/study/NCT05499390> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(24)02722-3> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Zhou C, Chen J, Wu L, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/akeso/>, <https://onco.cc/companies/summit-therapeutics/>, <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/first-line/> ;
  onco:people <https://onco.cc/people/zhou-caicun/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-trial-diversity/>, <https://onco.cc/bottlenecks/b-regulatory-fragmentation/> ;
  onco:journals <https://onco.cc/journals/lancet/> .